Novavax Inc - Company Profile

Powered by

All the data and insights you need on Novavax Inc in one report.

  • Save hours of research time and resources with
    our up-to-date Novavax Inc Strategy Report

  • Understand Novavax Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Novavax Inc (Novavax) is a biotechnology company that discovers, develops and commercializes vaccines to prevent a wide range of infectious diseases. The company develops genetically-engineered vaccine candidates harnessing three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. Its pipeline products include NVX-CoV2373 for coronavirus, NanoFlu for seasonal influenza, ResVax for respiratory syncytial syndrome and vaccines indicated for the prevention of Ebola virus, Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). It is also developing proprietary immune stimulating saponin-based adjuvants. The company operates research and manufacturing facilities in Gaithersburg, Maryland; Uppsala, Sweden; and Bohumil, Czech Republic. Novavax is headquartered in Gaithersburg, Maryland, the US.

Gain a 360-degree view of Novavax Inc and make more informed decisions for your business Gain a 360-degree view of Novavax Inc and make more informed decisions for your business Find out more
Headquarters United States of America

Address 700 Quince Orchard Road, Gaithersburg, Maryland, 20878


Telephone 1 240 2682000

No of Employees 1,543

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange NVAX (NASD)

Revenue (2023) $983.7M -50.4% (2023 vs 2022)

EPS XYZ

Net Income (2023) XYZ 17.2% (2023 vs 2022)

Market Cap* $740.4M

Net Profit Margin (2023) XYZ -66.9% (2023 vs 2022)

* As of and is in US$
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Novavax Inc premium industry data and analytics

110+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Novavax Inc’s relevant decision makers and contact details.

80+

Catalyst Calendar

Proactively evaluate Novavax Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

70+

Clinical Trials

Determine Novavax Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

30+

Pipeline Drugs

Identify which of Novavax Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

20+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

6

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Marketed Drugs

Understand Novavax Inc’s commercialized product portfolio to stay one step ahead of the market.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Novavax Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Pipeline NanoFlu
NVX-CoV2373 – Coronavirus ResVax
NanoFlu - Seasonal Influenza Vaccine Matrix-M
XYZ
XYZ
XYZ
Understand Novavax Inc portfolio and identify potential areas for collaboration Understand Novavax Inc portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Regulatory Approval In December, the company secured authorization from the Taiwan Food and Drug Administration for emergency use of Nuvaxovid XBB.1.5 dispersion for injection of COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) for active immunization to prevent COVID-19 in individuals aged 12 and older.
2023 Regulatory Approval In November, the company secured expanded authorization from Health Canada for Nuvaxovid XBB.1.5 Vaccine (Recombinant protein, Adjuvanted) (NVX-CoV2601) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 and older.
2023 Regulatory Approval In October, the company received full marketing authorisation from the Medicines and Healthcare Products Regulatory Agency (MHRA) for its prototype Covid-19 vaccine Nuvaxovid (NVX-CoV2373).
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Novavax Inc Merck & Co Inc Novartis AG AstraZeneca Plc GSK plc
Headquarters United States of America United States of America Switzerland United Kingdom United Kingdom
City Gaithersburg Kenilworth Basel Cambridge Brentford
State/Province Maryland New Jersey - England England
No. of Employees 1,543 72,000 76,057 89,900 70,212
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
James F. Young, Ph.D. Chairman Executive Board 2011 70
John C. Jacobs Chief Executive Officer; President; Director Executive Board 2023 -
Jim Kelly Chief Financial Officer; Treasurer; Executive Vice President Senior Management 2021 57
John J. Trizzino Chief Operating Officer; President Senior Management 2023 63
Rick Crowley Chief Operating Officer; Executive Vice President Senior Management 2020 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Novavax Inc key executives to enhance your sales strategy Gain insight into Novavax Inc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward